SCHEMBL8928218

SCHEMBL8928218

OCCCCCCCCCCCCCCCCCCCCOO

nearest known ligand 0.40

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
LMNA P02545 2/20 0.40
MEN1 O00255 2/20 0.40
KMT2A Q03164 2/20 0.40
TSHR P16473 2/20 0.40
ALDH1A1 P00352 2/20 0.40
HSD17B10 Q99714 1/20 0.40
GAA P10253 1/20 0.37
SMN1; SMN2 Q16637 1/20 0.35
GPR84 Q9NQS5 1/20 0.35
FFAR1 O14842 1/20 0.35
FFAR4 Q5NUL3 1/20 0.35
THRB P10828 1/20 0.35
HTT P42858 1/20 0.35
MAPT P10636 1/20 0.35
ACHE P22303 6/20 0.34
MAPK1 P28482 1/20 0.32
MIF P14174 1/20 0.31
LOX P28300 1/20 0.30
AOC3 Q16853 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29831 1.00 LMNA (0.40) LMNAMEN1KMT2ATSHRALDH1A1
SCHEMBL30879 1.00 LMNA (0.40) LMNAMEN1KMT2ATSHRALDH1A1
SCHEMBL30793 1.00 LMNA (0.40) LMNAMEN1KMT2ATSHRALDH1A1
SCHEMBL2801674 1.00 LMNA (0.40) LMNAMEN1KMT2ATSHRALDH1A1
SCHEMBL31034 1.00
SCHEMBL30759 1.00
SCHEMBL2795953 1.00 LMNA (0.40) LMNAMEN1KMT2ATSHRALDH1A1
SCHEMBL386178 1.00 LMNA (0.40) LMNAMEN1KMT2ATSHRALDH1A1
SCHEMBL30599 0.97
SCHEMBL16595111 0.91 GAA (0.47) LMNAMEN1KMT2ATSHRALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-5698101-A Hollow fiber membranes MEMTEC LIMITED (AU) 1997-12-16 US claimed
US-20240050573-A1 LYMPH DIRECTING PRODRUGS MONASH UNIVERSITY (AU) 2024-02-15 US disclosed
US-11738087-B2 Lymph directing prodrugs MONASH UNIVERSITY (AU) 2023-08-29 US disclosed
CN-115702171-A Emulsion of di-sec-butyl peroxydicarbonate 阿科玛法国公司 2023-02-14 CN disclosed
CN-115667319-A Organic peroxide emulsions with ethanol 阿科玛法国公司 2023-01-31 CN disclosed
US-20220211664-A1 LYMPH DIRECTING PRODRUGS MONASH UNIVERSITY (AU) 2022-07-07 US disclosed
US-11311512-B2 Lymph directing prodrugs MONASH UNIVERSITY (AU) 2022-04-26 US disclosed
US-20190105299-A1 LYMPH DIRECTING PRODRUGS MONASH UNIVERSITY (AU) 2019-04-11 US disclosed
US-20180243425-A1 LYMPH DIRECTING PRODRUGS MONASH UNIVERSITY (AU) 2018-08-30 US disclosed
US-20170326103-A1 LYMPH DIRECTING PRODRUGS MONASH UNIVERSITY (AU) 2017-11-16 US disclosed
EP-3180349-A1 LYMPH DIRECTING PRODRUGS Monash University (AU) 2017-06-21 EP disclosed
EP-3027216-A1 COMPOSITIONS AND PREPARATION METHODS OF LOW MELTING IONIC SALTS OF POORLY- WATER SOLUBLE DRUGS MW Encap Limited (GB) 2016-06-08 EP disclosed
US-20160151503-A1 COMPOSITIONS AND PREPARATION METHODS OF LOW MELTING IONIC SALTS OF POORLY-WATER SOLUBLE DRUGS MW ENCAP LIMITED (GB) 2016-06-02 US disclosed
WO-2016023082-A1 LYMPH DIRECTING PRODRUGS MONASH UNIVERSITY (AU) 2016-02-18 WO disclosed
CN-101484149-B There is the pharmaceutical dosage form of the separate layer of multilamellar EVONIK ROHM GMBH (DE) 2015-12-02 CN disclosed
WO-2015013772-A1 COMPOSITIONS AND PREPARATION METHODS OF LOW MELTING IONIC SALTS OF POORLY- WATER SOLUBLE DRUGS MONASH UNIVERSITY (AU) 2015-02-05 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240050573-A1 LYMPH DIRECTING PRODRUGS LTA, ABCB11, LYN LMNA 3766/4885MEN1 2306/4885KMT2A 4086/4885
US-20220211664-A1 LYMPH DIRECTING PRODRUGS LTA, ABCB11, LYN LMNA 3766/4885MEN1 2306/4885KMT2A 4086/4885
US-11311512-B2 Lymph directing prodrugs LTA, ABCB11, LYN LMNA 3766/4885MEN1 2306/4885KMT2A 4086/4885
US-20180243425-A1 LYMPH DIRECTING PRODRUGS MLNR, ABCB11, MLN LMNA 3302/4885MEN1 832/4885KMT2A 3956/4885
US-11738087-B2 Lymph directing prodrugs MLNR, ABCB11, MLN LMNA 3302/4885MEN1 832/4885KMT2A 3956/4885
US-20190105299-A1 LYMPH DIRECTING PRODRUGS LTA, ABCB11, LYN LMNA 3766/4885MEN1 2306/4885KMT2A 4086/4885
US-20170326103-A1 LYMPH DIRECTING PRODRUGS LTA, ABCB11, LYN LMNA 3766/4885MEN1 2306/4885KMT2A 4086/4885
US-20160151503-A1 COMPOSITIONS AND PREPARATION METHODS OF LOW MELTING IONIC SALTS OF POORLY-WATER SOLUBLE DRUGS ABCG2, SLC7A1, ABCB11 LMNA 1172/4885MEN1 3730/4885KMT2A 4481/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.